The clinical implications of the genetics of renal cell carcinoma

被引：48

作者：

Rosner, Inger ^{[1
]}

Bratslavsky, Gennady ^{[1
]}

Pinto, Peter A. ^{[1
]}

Linehan, W. Marston ^{[1
]}

机构：

[1] NCI, Urol Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2009年 / 27卷 / 02期

关键词：

Renal cell carcinoma; Gene; VHL; BHD; HPRC; HLRCC; HIPPEL-LINDAU-DISEASE; TUMOR-SUPPRESSOR GENE; GERMLINE MUTATIONS; FUMARATE-HYDRATASE; HEREDITARY LEIOMYOMATOSIS; SPONTANEOUS PNEUMOTHORAX; CANCER; FAMILIES; HIF; IDENTIFICATION;

D O I：

10.1016/j.urolonc.2008.11.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Over the last several decades, the advances in molecular genetics have elucidated kidney cancer gene pathways. Kidney cancer is a heterogeneous disorder. Each specific type of kidney cancer has its own histologic features, gene, and clinical course. Insight into the genetic basis of kidney cancer has been learned largely from the study of the familial or hereditary forms of kidney cancer. Extirpative surgery is currently the treatment of choice for kidney cancer that is confined to the kidney. Treatment for advanced or metastatic kidney cancer is a formidable challenge with the traditional therapies currently available. However, investigation of the Mendelian single-gene syndromes, like von Hippel Lindau (VHL: VHL gene), hereditary papillary renal carcinoma (HPRC: c-Met gene), Birt-Hogg-Dube (BHD: BHD gene), and hereditary leiomyomatosis renal cell cancer (HLRCC: fumarate hydratase gene) provides an opportunity to develop pathway specific therapies. Advances in molecular therapeutics offer novel treatment options for patients with advanced disease. Published by Elsevier Inc.

引用

页码：131 / 136

页数：6

共 55 条

[1]

[Anonymous], 2007, SEER Cancer Statistics Review, 1975-2004

[2] IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT [J].

BOTTARO, DP ;

RUBIN, JS ;

FALETTO, DL ;

CHAN, AML ;

KMIECIK, TE ;

VANDEWOUDE, GF ;

AARONSON, SA .

SCIENCE, 1991, 251 (4995) :802-804

[3] Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes [J].

Brugarolas, J ;

Kaelin, WG .

CANCER CELL, 2004, 6 (01) :7-10

[4] GERMLINE MUTATIONS IN THE VONHIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE - CORRELATIONS WITH PHENOTYPE [J].

CHEN, F ;

KISHIDA, T ;

YAO, M ;

HUSTAD, T ;

GLAVAC, D ;

DEAN, M ;

GNARRA, JR ;

ORCUTT, ML ;

DUH, FM ;

GLENN, G ;

GREEN, J ;

HSIA, YE ;

LAMIELL, J ;

LI, H ;

WEI, MH ;

SCHMIDT, L ;

TORY, K ;

KUZMIN, I ;

STACKHOUSE, T ;

LATIF, F ;

LINEHAN, WM ;

LERMAN, M ;

ZBAR, B .

HUMAN MUTATION, 1995, 5 (01) :66-75

[5] Rising incidence of renal cell cancer in the United States [J].

Chow, WH ;

Devesa, SS ;

Warren, JL ;

Fraumeni, JF .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1628-1631

[6] Imaging features of hereditary papillary renal cancers [J].

Choyke, PL ;

Walther, MM ;

Glenn, GM ;

Wagner, JR ;

Venzon, DJ ;

Lubensky, IA ;

Zbar, B ;

Linehan, WM .

JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1997, 21 (05) :737-741

[7] INHIBITION OF TRANSCRIPTION ELONGATION BY THE VHL TUMOR-SUPPRESSOR PROTEIN [J].

DUAN, DR ;

PAUSE, A ;

BURGESS, WH ;

ASO, T ;

CHEN, DYT ;

GARRETT, KP ;

CONAWAY, RC ;

CONAWAY, JW ;

LINEHAN, WM ;

KLAUSNER, RD .

SCIENCE, 1995, 269 (5229) :1402-1406

[8] The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease [J].

Duffey, BG ;

Choyke, PL ;

Glenn, G ;

Grubb, RL ;

Venzon, D ;

Linehan, WM ;

Walther, MM .

JOURNAL OF UROLOGY, 2004, 172 (01) :63-65

[9] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[10] MUTATIONS OF THE VHL TUMOR-SUPPRESSOR GENE IN RENAL-CARCINOMA [J].

GNARRA, JR ;

TORY, K ;

WENG, Y ;

SCHMIDT, L ;

WEI, MH ;

LI, H ;

LATIF, F ;

LIU, S ;

CHEN, F ;

DUH, FM ;

LUBENSKY, I ;

DUAN, DR ;

FLORENCE, C ;

POZZATTI, R ;

WALTHER, MM ;

BANDER, NH ;

GROSSMAN, HB ;

BRAUCH, H ;

POMER, S ;

BROOKS, JD ;

ISAACS, WB ;

LERMAN, MI ;

ZBAR, B ;

LINEHAN, WM .

NATURE GENETICS, 1994, 7 (01) :85-90

← 1 2 3 4 5 6 →